SRRK Stock News & Catalysts – Scholar Rock

FEATURED

Scholar Rock to Present at Upcoming Investor Conferences

Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin

Summary

Nov 3, 2026, 8:00 AM ·Business Wire

RECENT

Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

Scholar Rock (NASDAQ:SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets open. The Company will host a conference call and

Oct 20, 2026, 8:00 AM ·Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the Company granted inducement equity awards covering an aggregate of 61,020 shares of its common stock to seven newly hired employees, consisting

Oct 16, 2026, 4:15 PM ·Business Wire

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Apitegromab MAA resubmission includes alternate fill-finish facility in place of Catalent Indiana LLC (part of Novo Nordisk), in alignment with guidance from EMA Alternate fill-finish facility in MAA is the same

Oct 8, 2026, 8:00 AM ·Business Wire

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ:SRRK) breached their fiduciary

Sep 30, 2026, 9:56 AM ·PRNewswire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 83,102 shares of its common stock to ten newly hired employees, consisting

Sep 21, 2026, 12:00 PM ·Business Wire

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

ISEMBYLD is approved for use in all adults and children ≥2 years of age with SMA who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment ISEMBYLD recommended dose of 10 mg/kg showed a

Sep 11, 2026, 6:25 PM ·Business Wire

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

Apitegromab for FSHD granted Fast Track and Orphan Drug designations by FDA Dosing underway in Phase 2 FORGE trial; FSHD program expands Scholar Rock’s global leadership in myostatin biology across rare

Sep 2, 2026, 8:00 AM ·Business Wire

Scholar Rock to Present at Upcoming Investor Conferences

Aug 27, 2026, 8:00 AM ·Business Wire

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

Under FDA guidance, Scholar Rock has successfully removed Catalent Indiana LLC (part of Novo Nordisk) as a commercial fill-finish facility from apitegromab Biologics License Application (BLA) for spinal muscular

Aug 21, 2026, 9:06 AM ·Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly hired employees,

Aug 14, 2026, 4:15 PM ·Business Wire

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish facility as

Aug 7, 2026, 4:20 PM ·Business Wire

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval decision by

Aug 6, 2026, 7:00 AM ·Business Wire

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular

Jul 29, 2026, 8:00 AM ·Business Wire

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

NEW YORK, July 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ:SRRK) breached their fiduciary

Jul 28, 2026, 7:14 PM ·PRNewswire

Scholar Rock Holding Corporation SRRK · News